Our studies demonstrate that expression of MUC1-C in classic NE SCLC-A, variant NE SCLC-N, and non-NE SCLC-P cells activates the MYC pathway, which is dysregulated in SCLC cells and promotes tumor progression, drug resistance, and poor clinical outcomes (1). The gene discussed is MYC; the disease is neoplasm.